Trial reportJournal of translational medicine2013
Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis.
Trial report in Journal of translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Shared genetic risk factors and causal association between psoriasis and coronary artery disease.Nature communications · 2022Pooled it
- Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.Circulation. Cardiovascular imaging · 2018Trial
- Common Skin Diseases and Metabolic Syndrome: A Proinflammatory Chemokine Perspective.Metabolites · 2026Review
- Review
- Cutaneous papillomaviruses infection rewires fatty-acid metabolism.Frontiers in cellular and infection microbiology · 2026Article
- Skin Metabolic Signatures of Psoriasis and Psoriasis Concurrent with Metabolic Syndrome.Journal of inflammation research · 2025Article
- Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways.International journal of molecular sciences · 2022Review
- New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.The Journal of investigative dermatology · 2021Review
- Psoriasis and Atherosclerosis-Skin, Joints, and Cardiovascular Story of Two Plaques in Relation to the Treatment with Biologics.International journal of molecular sciences · 2021Review
- Effects of Dietary Protein Intake on Cutaneous and Systemic Inflammation in Mice with Acute Experimental Psoriasis.Nutrients · 2021Article
- Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.Dermatology and therapy · 2021Review
- Novel anti-inflammatory therapies to reduce cardiovascular burden of psoriasis.Dermatologic therapy · 2021Review
- Exploring the Pathogenesis of Psoriasis Complicated With AtherosclerosisFrontiers in immunology · 2021Article
- Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.Trends in cardiovascular medicine · 2020Review
- Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis.Journal of psoriasis and psoriatic arthritis · 2020Article
- The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic.International journal of molecular sciences · 2020Review
- Article
- Review-Current Concepts in Inflammatory Skin Diseases Evolved by Transcriptome Analysis: In-Depth Analysis of Atopic Dermatitis and Psoriasis.International journal of molecular sciences · 2020Review
- Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.Frontiers in immunology · 2018Review
- IFN-γ and TNF-α synergism may provide a link between psoriasis and inflammatory atherogenesis.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundModerate-to-severe psoriasis is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD); however, the link is poorly understood.
methodsSkin and serum from patients with psoriasis were evaluated to understand if there was evidence of dysregulation in a targeted group of inflammatory and lipid genes related to ASCVD. Microarray analyses of expression of targeted ASCVD genes from skin in 89 patients with moderate-to-severe psoriasis from the ACCEPT trial were compared with non-diseased skin from healthy controls (n = 25). Serum (n = 149) was tested at baseline for monocyte chemoattractant protein-1 (MCP-1), macrophage-derived chemokine (MDC), and apolipoprotein-A1 (Apo-A1) comparing to healthy controls (n=162).
resultsAn increase in skin gene expression for MCP-1 (7.98-fold) and MDC (6.66-fold) (p < 0.001 each) was observed in lesional versus healthy skin. Significant decreases in liver X receptor-alpha (LXR-α) (-5.94-fold), a protective lipoprotein metabolism gene, and in peroxisome proliferator-activated receptor-alpha (PPAR-α) (-7.58-fold), a protective anti-inflammatory and lipid modulating gene, were observed in lesional versus healthy skin (p < 0.001 each). Serum analyses revealed that MCP-1 (502 vs. 141 pg/mL) and MDC (1240 vs. 409 pg/mL) levels were significantly elevated in psoriasis compared with healthy controls (p < 0.001 each). Dysregulated lipid metabolism was also evident in the serum, as Apo-A1, a protein product related to PPAR-α activation, was significantly decreased in patients with psoriasis compared with healthy controls (25.2 vs. 38.9 mg/dL; p < 0.001).
conclusionsAnalyses of targeted genes and their products known to be associated with ASCVD revealed dysregulation of inflammatory (MCP-1 and MDC) and lipid metabolism (LXR-α, PPAR-α) genes in psoriasis. These findings provide evidence of a potential shared pathophysiology linking psoriasis to cardiometabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.